QianJin Pharmaceutical acquires equity in 2 subsidiaries to accelerate resource integration

Zhuzhou Qianjin Pharmaceutical Co., Ltd. has received approval from the China Securities Regulatory Commission, allowing the company to acquire 28.92% equity in Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd. and 68.00% equity in Hunan Qianjin Xieli Pharmaceutical Co., Ltd. through the issuance of shares and cash payment. This is the 14th licensed restructuring project approved by the Shanghai Stock Exchange this year. It is reported that this transaction will enhance Zhuzhou Guotou's control over the acquired companies, contributing to the improvement and efficiency of state-owned assets. After the transaction is completed, Zhuzhou Guotou's equity stake in the listed company will increase from 28.76% to 34.94%, which is beneficial for maintaining the stability of the listed company's governance and control